Dapagliflozin exerts benefits by inhibiting TGF-β/Smad signaling, thus ameliorating myocardial fibrosis in a manner common to the physiological implications of miR-29 as previously described [92]. This evidence concerns the gene TGFB1 and Myocardial fibrosis.